{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T17:12:13Z","timestamp":1776532333327,"version":"3.51.2"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,5,4]],"date-time":"2021-05-04T00:00:00Z","timestamp":1620086400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,5,4]],"date-time":"2021-05-04T00:00:00Z","timestamp":1620086400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The development of direct-acting antivirals (DAA) for HCV has revolutionized the treatment of HCV, including its treatment in patients with HIV coinfection. The aim of this study was to compare the changes in liver function between coinfected and monoinfected patients with cirrhosis who achieved HCV eradication by DAA.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Patients with pre-treatment diagnosis of HCV liver cirrhosis, consecutively enrolled in the multicenter PITER cohort, who achieved a sustained virological response 12\u2009weeks after treatment cessation (SVR12) were analysed. Changes in Child-Pugh (C-P) class and the occurrence of a decompensating event was prospectively evaluated after the end of DAA treatment. Cox regression analysis was used to evaluate factors independently associated with changes in liver function following viral eradication.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We evaluated 1350 patients, of whom 1242 HCV monoinfected (median follow-up 24.7, range 6.8\u201347.5\u2009months after viral eradication) and 108 (8%) HCV\/HIV coinfected (median follow-up 27.1, range 6.0\u201344.6).<\/jats:p>\n                <jats:p>After adjusting for age, sex, HCV-genotype, HBsAg positivity and alcohol use, HIV was independently associated with a more advanced liver disease before treatment (C-P class B\/C vs A) (OR: 3.73, 95% CI:2.00\u20136.98). Following HCV eradication, C-P class improved in 17\/20 (85%) coinfected patients (from B to A and from C to B) and in 53\/82 (64.6%) monoinfected patients (from B to A) (<jats:italic>p<\/jats:italic>\u2009=\u20090.08). C-P class worsened in 3\/56 coinfected (5.3%) (from A to B) and in 84\/1024 (8.2%) monoinfected patients (<jats:italic>p<\/jats:italic>\u2009=\u20090.45) (from A to B or C and from B to C).<\/jats:p>\n                <jats:p>Baseline factors independently associated with C-P class worsening were male sex (HR\u2009=\u20092.00; 95% CI\u2009=\u20091.18\u20133.36), platelet count &lt;\u2009100,000\/\u03bcl (HR\u2009=\u20091.75; 95% CI 1.08\u20132.85) and increased INR (HR\u2009=\u20092.41; 95% CI 1.51\u20133.84). Following viral eradication, in 7 of 15 coinfected (46.6%) and in 61 of 133 (45.8%) monoinfected patients with previous history of decompensation, a new decompensating event occurred. A first decompensating event was recorded in 4 of 93 (4.3%) coinfected and in 53 of 1109 (4.8%) monoinfected patients (<jats:italic>p<\/jats:italic>\u2009=\u00a00.83).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Improvement of liver function was observed following HCV eradication in the majority of patients with cirrhosis; however viral eradication did not always mean cure of liver disease in both monoinfected and coinfected patients with advanced liver disease.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12879-021-06053-3","type":"journal-article","created":{"date-parts":[[2021,5,4]],"date-time":"2021-05-04T09:03:27Z","timestamp":1620119007000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Liver function following hepatitis C virus eradication by direct acting antivirals in patients with liver cirrhosis: data from the PITER cohort"],"prefix":"10.1186","volume":"21","author":[{"given":"Maria Giovanna","family":"Quaranta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luigina","family":"Ferrigno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xhimi","family":"Tata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franca","family":"D\u2019Angelo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmine","family":"Coppola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessia","family":"Ciancio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Serena Rita","family":"Bruno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martina","family":"Loi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessia","family":"Giorgini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marzia","family":"Margotti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentina","family":"Cossiga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppina","family":"Brancaccio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcello","family":"Dallio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martina","family":"De Siena","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Cannizzaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luisa","family":"Cavalletto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Massari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Mazzitelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pasqualina","family":"De Leo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diletta","family":"Laccabue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonardo","family":"Baiocchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Loreta A.","family":"Kondili","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,5,4]]},"reference":[{"issue":"10179","key":"6053_CR1","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1016\/S0140-6736(18)32111-1","volume":"393","author":"F Carrat","year":"2019","unstructured":"Carrat F, Fontaine H, Dorival C, Simony M, Diallo A, Hezode C, et al. Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study. Lancet. 2019;393(10179):1453\u201364. https:\/\/doi.org\/10.1016\/S0140-6736(18)32111-1.","journal-title":"Lancet."},{"issue":"10","key":"6053_CR2","doi-asserted-by":"publisher","first-page":"e0185728","DOI":"10.1371\/journal.pone.0185728","volume":"12","author":"LA Kondili","year":"2017","unstructured":"Kondili LA, Gaeta GB, Brunetto MR, di Leo A, Iannone A, Santantonio TA, et al. Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: interim evaluations from the PITER network. PLoS One. 2017;12(10):e0185728. https:\/\/doi.org\/10.1371\/journal.pone.0185728.","journal-title":"PLoS One"},{"key":"6053_CR3","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1007\/s12072-020-10034-0","volume":"14","author":"MG Quaranta","year":"2020","unstructured":"Quaranta MG, Ferrigno L, Monti M, et al. PITER Collaborating Group. Advanced liver disease outcomes after hepatitis C eradication by human immunodeficiency virus infection in PITER cohort. Hepatol Int. 2020;14:362\u201372.","journal-title":"Hepatol Int"},{"issue":"6","key":"6053_CR4","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1016\/j.jhep.2020.08.006","volume":"73","author":"V Calvaruso","year":"2020","unstructured":"Calvaruso V, Crax\u00ec A. Hepatic benefits of HCV cure. J Hepatol. 2020;73(6):1548\u201356. https:\/\/doi.org\/10.1016\/j.jhep.2020.08.006.","journal-title":"J Hepatol"},{"issue":"1","key":"6053_CR5","doi-asserted-by":"publisher","first-page":"S95","DOI":"10.1016\/j.jhep.2016.07.039","volume":"65","author":"AJ van der Meer","year":"2016","unstructured":"van der Meer AJ, Berenguer M. Reversion of disease manifestations after HCV eradication. J Hepatol. 2016;65(1):S95\u2013S108. https:\/\/doi.org\/10.1016\/j.jhep.2016.07.039.","journal-title":"J Hepatol"},{"issue":"3","key":"6053_CR6","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.jhep.2020.03.031","volume":"73","author":"EC Verna","year":"2020","unstructured":"Verna EC, Morelli G, Terrault NA, Lok AS, Limet JK, et al. DAA therapy and long-term hepatic function in advanced\/decompensated cirrhosis: Real-world experience from HCV-TARGET cohort. J Hepatol. 2020; https:\/\/doi.org\/10.1016\/j.jhep.2020.03.031;73(3):540\u20138.","journal-title":"J Hepatol"},{"issue":"7","key":"6053_CR7","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/S1473-3099(04)01059-X","volume":"4","author":"JK Rockstroh","year":"2004","unstructured":"Rockstroh JK, Spengler U. HIV and hepatitis C virus coinfection. Lancet Infect Dis. 2004;4(7):437\u20134. https:\/\/doi.org\/10.1016\/S1473-3099(04)01059-X.","journal-title":"Lancet Infect Dis"},{"issue":"6","key":"6053_CR8","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1038\/nrgastro.2014.17","volume":"11","author":"JY Chen","year":"2014","unstructured":"Chen JY, Feeney ER, Chung RT. HCV and HIV co-infection: mechanisms and management. Nat Rev Gastroenterol Hepatol. 2014;11(6):362\u201371. https:\/\/doi.org\/10.1038\/nrgastro.2014.17.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"10","key":"6053_CR9","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1093\/cid\/cit537","volume":"57","author":"J Mac\u00edas","year":"2013","unstructured":"Mac\u00edas J, M\u00e1rquez M, T\u00e9llez F, Merino D, Jim\u00e9nez-Aguilar P, et al. Risk of liver decompensation among HIV\/hepatitis C virus-coinfected individuals with advanced fibrosis: implications for the timing of therapy. Clin Infect Dis. 2013;57(10):1401\u20138. https:\/\/doi.org\/10.1093\/cid\/cit537.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"6053_CR10","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1093\/cid\/cis777","volume":"56","author":"N Merchante","year":"2013","unstructured":"Merchante N, Merino E, L\u00f3pez-Aldeguer J, Jover F, Delgado-Fern\u00e1ndez M, Galindo MJ, et al. Increasing incidence of hepatocellular carcinoma in HIV-infected patients in Spain. Clin Infect Dis. 2013;56(1):143\u201350. https:\/\/doi.org\/10.1093\/cid\/cis777.","journal-title":"Clin Infect Dis"},{"issue":"4","key":"6053_CR11","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/j.jhep.2012.06.010","volume":"57","author":"V Hernando","year":"2012","unstructured":"Hernando V, Perez-Cachafeiro S, Lewden C, Gonzalez J, Segura F, Oteo JA, et al. All-cause and liver-related mortality in HIV positive subjects compared to the general population: differences by HCV co-infection. J Hepatol. 2012;57(4):743\u201351. https:\/\/doi.org\/10.1016\/j.jhep.2012.06.010.","journal-title":"J Hepatol"},{"issue":"8","key":"6053_CR12","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1086\/605676","volume":"49","author":"JA Pineda","year":"2009","unstructured":"Pineda JA, Aguilar-Guisado M, Rivero A, Ruiz-Morales J, Merino D, R\u00edos-Villegas MJ, et al. Natural history of compensated hepatitis C virus-related cirrhosis in HIV-infected patients. Clin Infect Dis. 2009;49(8):1274\u201382. https:\/\/doi.org\/10.1086\/605676.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"6053_CR13","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1056\/NEJMoa1306218","volume":"370","author":"MS Sulkowski","year":"2014","unstructured":"Sulkowski MS, Gardiner DF, Rodriguez-Torres M, Reddy KR, Hassanein T, Jacobson I, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med. 2014;370(3):211\u201321. https:\/\/doi.org\/10.1056\/NEJMoa1306218.","journal-title":"N Engl J Med"},{"issue":"16","key":"6053_CR14","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1056\/NEJMoa1316366","volume":"370","author":"N Afdhal","year":"2014","unstructured":"Afdhal N, Reddy KR, Nelson DR, Lawitz E, Gordon SC, Schiff E, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med. 2014;370(16):1483\u201393. https:\/\/doi.org\/10.1056\/NEJMoa1316366.","journal-title":"N Engl J Med"},{"issue":"3","key":"6053_CR15","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1097\/MOG.0000000000000347","volume":"33","author":"EG Meissner","year":"2017","unstructured":"Meissner EG. Update in HIV\/HCV co-infection in the direct acting antiviral era. Curr Opin Gastroenterol. 2017;33(3):120\u20137. https:\/\/doi.org\/10.1097\/MOG.0000000000000347.","journal-title":"Curr Opin Gastroenterol"},{"issue":"3","key":"6053_CR16","doi-asserted-by":"publisher","first-page":"e13056","DOI":"10.1111\/eci.13056","volume":"49","author":"EG Giannini","year":"2019","unstructured":"Giannini EG, Crespi M, Demarzo M, Bodini G, Furnari M, Marabotto E, et al. Improvement in hepatitis C virus patients with advanced, compensated liver disease after sustained virological response to direct acting antivirals. Eur J Clin Investig. 2019;49(3):e13056. https:\/\/doi.org\/10.1111\/eci.13056.","journal-title":"Eur J Clin Investig"},{"issue":"1","key":"6053_CR17","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.jhep.2017.02.012","volume":"67","author":"L Piroth","year":"2017","unstructured":"Piroth L, Wittkop L, Lacombe K, Rosenthal E, Gilbert C, Miailhes P, et al. Efficacy and safety of direct-acting antiviral regimens in HIV\/HCV-co-infected patients - French ANRS CO13 HEPAVIH cohort. J Hepatol. 2017;67(1):23\u201331. https:\/\/doi.org\/10.1016\/j.jhep.2017.02.012.","journal-title":"J Hepatol"},{"issue":"9","key":"6053_CR18","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/j.dld.2015.05.022","volume":"47","author":"LA Kondili","year":"2015","unstructured":"Kondili LA, Vella S. PITER collaborating. PITER: an ongoing nationwide study on the real-life impact of direct acting antiviral based treatment for chronic hepatitis C in Italy. Dig Liver Dis. 2015;47(9):741\u20133. https:\/\/doi.org\/10.1016\/j.dld.2015.05.022.","journal-title":"Dig Liver Dis"},{"issue":"1","key":"6053_CR19","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1002\/hep.20506","volume":"41","author":"M Ziol","year":"2005","unstructured":"Ziol M, Handra-Luca A, Kettaneh A, Christidis C, Mal F, Kazemi F, et al. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. Hepatology. 2005;41(1):48\u201354. https:\/\/doi.org\/10.1002\/hep.20506.","journal-title":"Hepatology."},{"issue":"2","key":"6053_CR20","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1053\/j.gastro.2004.11.018","volume":"128","author":"L Cast\u00e9ra","year":"2005","unstructured":"Cast\u00e9ra L, Vergniol J, Foucher J, le Bail B, Chanteloup E, Haaser M, et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology. 2005;128(2):343\u201350. https:\/\/doi.org\/10.1053\/j.gastro.2004.11.018.","journal-title":"Gastroenterology."},{"issue":"4","key":"6053_CR21","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1002\/hep.510260431","volume":"26","author":"V Guadagnino","year":"1997","unstructured":"Guadagnino V, Stroffolini T, Rapicetta M, Costantino A, Kondili LA, Menniti-Ippolito F, et al. Prevalence, risk factors, and genotype distribution of hepatitis C virus infection in the general population: a community-based survey in southern Italy. Hepatology. 1997;26(4):1006\u20131. https:\/\/doi.org\/10.1002\/hep.510260431.","journal-title":"Hepatology."},{"issue":"1 Suppl","key":"6053_CR22","doi-asserted-by":"publisher","first-page":"S58","DOI":"10.1016\/j.jhep.2014.07.012","volume":"61","author":"RH Westbrook","year":"2014","unstructured":"Westbrook RH, Dusheiko G. Natural history of hepatitis C. J Hepatol. 2014;61(1 Suppl):S58\u201368. https:\/\/doi.org\/10.1016\/j.jhep.2014.07.012 Epub 2014 Nov 3. PMID: 25443346.","journal-title":"J Hepatol"},{"issue":"1 Suppl","key":"6053_CR23","doi-asserted-by":"publisher","first-page":"S120","DOI":"10.1016\/j.jhep.2016.08.001","volume":"65","author":"NA Terrault","year":"2016","unstructured":"Terrault NA, Hassanein TI. Management of the patient with SVR. J Hepatol. 2016;65(1 Suppl):S120\u20139. https:\/\/doi.org\/10.1016\/j.jhep.2016.08.001.","journal-title":"J Hepatol"},{"key":"6053_CR24","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.jhep.2018.03.026","volume":"69","author":"European Association for the Study of the Liver","year":"2018","unstructured":"European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2018. J Hepatol. 2018;69:461\u2013511.","journal-title":"J Hepatol"},{"issue":"7","key":"6053_CR25","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1097\/QAD.0000000000002186","volume":"33","author":"A Corma-G\u00f3mez","year":"2019","unstructured":"Corma-G\u00f3mez A, Morano L, T\u00e9llez F, Rivero-Ju\u00e1rez A, Real LM, Alados JC, et al. HIV infection does not increase the risk of liver complications in hepatitis C virus-infected patient with advanced fibrosis, after sustained virological response with direct-acting antivirals. AIDS. 2019;33(7):1167\u201374. https:\/\/doi.org\/10.1097\/QAD.0000000000002186.","journal-title":"AIDS."},{"issue":"1","key":"6053_CR26","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1111\/jvh.12990","volume":"26","author":"J Mac\u00edas","year":"2019","unstructured":"Mac\u00edas J, Granados R, T\u00e9llez F, Merino D, P\u00e9rez M, Morano LE, et al. Similar recovery of liver function after response to all-oral HCV therapy in patients with cirrhosis with and without HIV coinfection. J Viral Hepat. 2019;26(1):16\u201324. https:\/\/doi.org\/10.1111\/jvh.12990.","journal-title":"J Viral Hepat"},{"issue":"16","key":"6053_CR27","doi-asserted-by":"publisher","first-page":"2347","DOI":"10.1097\/QAD.0000000000001966","volume":"32","author":"GM Lled\u00f3","year":"2018","unstructured":"Lled\u00f3 GM, Carrasco I, Ben\u00edtez-Guti\u00e9rrez LM, Arias A, Royuela A, Requena S, et al. Regression of liver fibrosis after curing chronic hepatitis C with oral antivirals in patients with and without HIV coinfection. AIDS. 2018;32(16):2347\u201352. https:\/\/doi.org\/10.1097\/QAD.0000000000001966.","journal-title":"AIDS."},{"issue":"8","key":"6053_CR28","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1053\/j.gastro.2018.03.022","volume":"154","author":"O El-Sherif","year":"2018","unstructured":"El-Sherif O, Jiang ZG, Tapper EB, Huang KC, Zhong A, et al. Baseline factors associated with improvements in decompensated cirrhosis after direct-acting antiviral therapy for hepatitis C virus infection. Gastroenterology. 2018;154(8):2111\u201321. https:\/\/doi.org\/10.1053\/j.gastro.2018.03.022.","journal-title":"Gastroenterology."},{"issue":"3","key":"6053_CR29","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/j.jhep.2016.05.010","volume":"65","author":"LS Belli","year":"2016","unstructured":"Belli LS, Berenguer M, Cortesi PA, Strazzabosco M, Rockenschaub SR, Martini S, et al. Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: a European study. J Hepatol. 2016;65(3):524\u201331. https:\/\/doi.org\/10.1016\/j.jhep.2016.05.010.","journal-title":"J Hepatol"},{"issue":"6","key":"6053_CR30","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1002\/hep.29097","volume":"65","author":"C Fernandez Carrillo","year":"2017","unstructured":"Fernandez Carrillo C, Lens S, Llop E, Pascasio JM, Crespo J, et al. Treatment of hepatitis C virus infection in patients with cirrhosis and predictive value of model for end-stage liver disease: analysis of data from the Hepa-C registry. Hepatology. 2017;65(6):1810\u201322. https:\/\/doi.org\/10.1002\/hep.29097.","journal-title":"Hepatology."},{"issue":"5","key":"6053_CR31","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1097\/TP.0000000000001708","volume":"101","author":"NA Terrault","year":"2017","unstructured":"Terrault NA, McCaughan GW, Curry MP, Gane E, Fagiuoli S, et al. International liver transplantation society consensus statement on hepatitis C management in liver transplant candidates. Transplantation. 2017;101(5):945\u201355. https:\/\/doi.org\/10.1097\/TP.0000000000001708.","journal-title":"Transplantation."},{"issue":"1","key":"6053_CR32","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1007\/s12072-018-9914-6","volume":"13","author":"I Gentile","year":"2019","unstructured":"Gentile I, Scotto R, Coppola C, Staiano L, Amoruso DC, de Simone T, et al. Treatment with direct-acting antivirals improves the clinical outcome in patients with HCV-related decompensated cirrhosis: results from an Italian real-life cohort (Liver Network Activity-LINA cohort). Hepatol Int. 2019;13(1):66\u201374. https:\/\/doi.org\/10.1007\/s12072-018-9914-6.","journal-title":"Hepatol Int"},{"issue":"27","key":"6053_CR33","doi-asserted-by":"publisher","first-page":"2618","DOI":"10.1056\/NEJMoa1512614","volume":"373","author":"MP Curry","year":"2015","unstructured":"Curry MP, O'Leary JG, Bzowej N, et al. Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis. N Engl J Med. 2015;373(27):2618\u201328. https:\/\/doi.org\/10.1056\/NEJMoa1512614.","journal-title":"N Engl J Med"},{"issue":"8","key":"6053_CR34","doi-asserted-by":"publisher","first-page":"626","DOI":"10.17235\/reed.2019.6086\/2018","volume":"111","author":"L Dom\u00ednguez Dom\u00ednguez","year":"2019","unstructured":"Dom\u00ednguez Dom\u00ednguez L, Matarranz M, Lagarde M, Bisbal O, Hernando A, Lumbreras C, et al. HCV eradication with all-oral therapy in cirrhotic HIV-coinfected patients: an observational study of early changes in liver function and fibrosis tests. Rev Esp Enferm Dig. 2019;111(8):626\u201332. https:\/\/doi.org\/10.17235\/reed.2019.6086\/2018.","journal-title":"Rev Esp Enferm Dig"},{"issue":"11","key":"6053_CR35","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1111\/jvh.12945","volume":"25","author":"R Flisiak","year":"2018","unstructured":"Flisiak R, Janczewska E, \u0141ucejko M, Karpi\u0144ska E, Zar\u0119bska-Michaluk D, Nazzal K, et al. Durability of virologic response, risk of de novo hepatocellular carcinoma, liver function and stiffness 2 years after treatment with ombitasvir\/paritaprevir\/ritonavir\u00b1dasabuvir\u00b1ribavirin in the AMBER, real-world experience study. J Viral Hepat. 2018;25(11):1298\u2013305. https:\/\/doi.org\/10.1111\/jvh.12945.","journal-title":"J Viral Hepat"},{"issue":"5","key":"6053_CR36","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1053\/j.gastro.2017.07.016","volume":"153","author":"S Lens","year":"2017","unstructured":"Lens S, Alvarado-Tapias E, Mari\u00f1o Z, Londo\u00f1o MC, LLop E, Martinez J, et al. Effects of all-oral anti-viral therapy on HVPG and systemic hemodynamics in patients with hepatitis C virus-associated cirrhosis. Gastroenterology. 2017;153(5):1273\u201383. https:\/\/doi.org\/10.1053\/j.gastro.2017.07.016.","journal-title":"Gastroenterology."},{"issue":"3","key":"6053_CR37","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/j.jhep.2019.10.005","volume":"72","author":"M Pons","year":"2020","unstructured":"Pons M, Rodr\u00edguez-Tajes S, Esteban JI, Mari\u00f1o Z, Vargas V, Lens S, et al. Non-invasive prediction of liver-related events in patients with HCV-associated compensated advanced chronic liver disease after oral antivirals. J Hepatol. 2020;72(3):472\u201380. https:\/\/doi.org\/10.1016\/j.jhep.2019.10.005.","journal-title":"J Hepatol"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-021-06053-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-021-06053-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-021-06053-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,4]],"date-time":"2021-05-04T09:05:35Z","timestamp":1620119135000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-021-06053-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,4]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["6053"],"URL":"https:\/\/doi.org\/10.1186\/s12879-021-06053-3","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,4]]},"assertion":[{"value":"21 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the guidelines of the Declaration of Helsinki and the principles of Good Clinical Practice. The study protocol was approved by the Ethics Committee of the Istituto Superiore di Sanit\u00e0 (Italian National Institute of Public Health) and by the local Ethics committees of each clinical center. The patients\u2019 data were evaluated through an anonymous analysis, adopting codes generated by the electronic case report forms. All patients gave their written informed consent to participate in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors declare no conflicts of interest regarding the present study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"413"}}